# Krascendo 1

Source: https://onco.cc/trials/krascendo-1/  
OnCo record `krascendo-1` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The first head-to-head trial among KRAS drugs: Roche's divarasib beat the two approved pills on progression and survival.

## Summary

Krascendo 1, trial NCT06497556 sponsored by Roche, is the first head-to-head trial among KRAS drugs, comparing divarasib with sotorasib or adagrasib in previously treated KRAS G12C-mutant non-small-cell lung cancer. Roche announced on 2 July 2026 that divarasib showed superior progression-free survival by blinded review and superior overall survival at an interim analysis against the two approved inhibitors, with full data expected at a 2026 congress from a trial of 338 patients. OnCo links it to KRAS as a target and to all three drugs, and notes that Krascendo 2 tests divarasib with pembrolizumab in the first line. Because the numbers are pending and this is the first such comparison, there is no independent replication, and whether a more potent G12C inhibitor changes the modest picture left by CodeBreaK 200 and KRYSTAL-12 is the open question. Divarasib has its own page.

## Fields

- Kind: Trial
- Status: positive
- Last checked: 2026-09-06
- Registry id: NCT06497556
- Phase: 3
- Setting: Previously treated KRAS G12C NSCLC: divarasib vs sotorasib or adagrasib
- Sponsor: Roche
- Enrolled: 338
- Result: Superior PFS and OS vs approved G12C inhibitors (topline, July 2026).
- Outcomes: Progression-free survival (BICR): Divarasib vs Sotorasib or adagrasib; Overall survival (interim): Divarasib vs Sotorasib or adagrasib
- Replication: Topline reported July 2026; numbers pending presentation. First head-to-head phase 3 among KRAS G12C inhibitors, so no independent replication yet.

## Sources

- ClinicalTrials.gov NCT06497556: https://clinicaltrials.gov/study/NCT06497556
- Roche release: https://www.roche.com/media/releases/med-cor-2026-07-02

## Connected records

- cancers: [KRAS G12C-mutant non-small-cell lung cancer](https://onco.cc/cancers/kras-g12c-nsclc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- technologies: [KRAS & RAS inhibitors](https://onco.cc/technologies/kras-inhibitors/)
- targets: [KRAS](https://onco.cc/targets/kras/)
- drugs: [Adagrasib](https://onco.cc/drugs/adagrasib/), [Divarasib](https://onco.cc/drugs/divarasib/), [Sotorasib](https://onco.cc/drugs/sotorasib/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)
- roadmaps: [Targeted therapy roadmap: imatinib → designed for resistance → the undruggable drivers fall](https://onco.cc/roadmaps/targeted-therapy-roadmap/)

---
JSON: https://onco.cc/api/v1/entities/krascendo-1.json